Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

October 31, 2000

Primary Completion Date

October 22, 2002

Study Completion Date

September 22, 2008

Conditions
Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer
Interventions
DRUG

lurtotecan liposome

Trial Locations (14)

T2N 4N2

Tom Baker Cancer Center - Calgary, Calgary

V1Y 5L3

BCCC - Cancer Center for the Southern Interior, Kelowna

V5Z 4E6

British Columbia Cancer Agency, Vancouver

R3E 0V9

CancerCare Manitoba, Winnipeg

B3H 1V7

Nova Scotia Cancer Centre, Halifax

K7L 3N6

Queen's University, Kingston

H3A 1A1

Royal Victoria Hospital - Montreal, Montreal

S7N 0XO

Royal University Hospital, Saskatoon

B18 7QH

City Hospital NHS Trust, Birmingham

SW3 6JJ

Royal Marsden NHS Trust, London

M20 4BX

Christie Hospital N.H.S. Trust, Manchester

NE4 6BE

Newcastle General Hospital, Newcastle upon Tyne

S1O 2SJ

Weston Park Hospital, Sheffield

G11 6NT

Beatson Oncology Centre, Glasgow

Sponsors
All Listed Sponsors
lead

NCIC Clinical Trials Group

NETWORK